Literature DB >> 20354458

Endobronchial ultrasound-guided transbronchial needle aspiration for lymph node staging in patients with non-small cell lung cancer in non-operable patients pursuing radiotherapy as a primary treatment.

Takahiro Nakajima1, Kazuhiro Yasufuku, Mio Nakajima, Masayuki Baba, Kyosan Yoshikawa, Tadashi Kamada, Kenzo Hiroshima, Yukio Nakatani, Takehiko Fujisawa, Ichiro Yoshino.   

Abstract

INTRODUCTION: Carbon ion radiotherapy (CIRT) is a promising modality with excellent localization and significant biologic effects on tumors. Nevertheless, success depends primarily on accurate staging before radiotherapy. Surgical interventions should be avoided in patients considered for CIRT because they usually have multiple comorbidities. The aim of this study was to evaluate the effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for lymph node staging in patients with non-small cell lung cancer before CIRT.
METHODS: From April 2005 to December 2007, 49 patients with non-small cell lung cancer considered for CIRT with abnormal positron emission tomography-computed tomography (PET-CT) accumulations in the mediastinum and/or hilum were evaluated by EBUS-TBNA. The convex probe EBUS was used for EBUS-TBNA.
RESULTS: There were 38 men and 11 women. Their mean age was 75.2 years (range: 55-87). Based on PET-CT, clinical staging was four with N1 disease, 42 with N2 disease, and three with N3 disease. By histology, 26 patients had adenocarcinoma, 19 had squamous cell carcinoma, and four had other histologies. All positive lymph nodes on PET-CT were aspirated (range: 1-5; average 2.55 lymph nodes/patient). EBUS-TBNA diagnosed 43 cases as N0 disease and as a result underwent CIRT. Forty of the 43 cases remained in stable condition without local recurrences (follow-up 6-46 months). The diagnostic accuracy of EBUS-TBNA for lymph node staging was 93.9%.
CONCLUSIONS: EBUS-TBNA offers accurate minimally invasive lymph node staging in patients who are candidates for CIRT. EBUS-TBNA can be safely performed with a high diagnostic accuracy before CIRT.

Entities:  

Mesh:

Year:  2010        PMID: 20354458     DOI: 10.1097/JTO.0b013e3181d35627

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  7 in total

Review 1.  Current status and perspective of EBUS-TBNA.

Authors:  Takahiro Nakajima; Kazuhiro Yasufuku; Ichiro Yoshino
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-02-26

2.  Impact of invasive nodal staging on regional and distant recurrence rates after SBRT for inoperable stage I NSCLC.

Authors:  William R Kennedy; Pamela P Samson; Prashant Gabani; John Nikitas; Jeffrey D Bradley; Michael C Roach; Clifford G Robinson
Journal:  Radiother Oncol       Date:  2020-07-03       Impact factor: 6.280

3.  Understanding local performance data for EBUS-TBNA: insights from an unselected case series at a high volume UK center.

Authors:  Vandana Jeebun; Richard Neil Harrison
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

4.  Systematic Endobronchial Ultrasound-guided Mediastinal Staging Versus Positron Emission Tomography for Comprehensive Mediastinal Staging in NSCLC Before Radical Radiotherapy of Non-small Cell Lung Cancer: A Pilot Study.

Authors:  Daniel P Steinfort; Shankar Siva; Tracy L Leong; Morgan Rose; Dishan Herath; Phillip Antippa; David L Ball; Louis B Irving
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

5.  Bronchial sleeve resection for early-stage squamous cell carcinoma.

Authors:  Taichiro Goto; Arafumi Maeshima; Kumi Akanabe; Ryoichi Kato
Journal:  J Cardiothorac Surg       Date:  2012-04-17       Impact factor: 1.637

Review 6.  Optimizing tissue sampling for the diagnosis, subtyping, and molecular analysis of lung cancer.

Authors:  Linda Marie Ofiara; Asma Navasakulpong; Stephane Beaudoin; Anne Valerie Gonzalez
Journal:  Front Oncol       Date:  2014-09-22       Impact factor: 6.244

Review 7.  Endoscopic ultrasound in the diagnosis and staging of lung cancer.

Authors:  Sara Colella; Peter Vilmann; Lars Konge; Paul Frost Clementsen
Journal:  Endosc Ultrasound       Date:  2014-10       Impact factor: 5.628

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.